ライフサイエンスコーパス: patent foramen ovale

1 , to medical therapy alone or closure of the patent foramen ovale.

2 c medications or percutaneous closure of the patent foramen ovale.

3 or transient ischemic attack (TIA) and had a patent foramen ovale.

4 ld, limited to pulmonary artery stenosis and patent foramen ovale.

5 DVT and paradoxical embolism due to existing patent foramen ovale.

6 and contrast transcranial doppler to detect patent foramen ovale.

7 Of 11 patients, 5 (45%) had a patent foramen ovale; 1 of these also had a primary lung

8 Patent foramen ovale, alone or together with ASA, was no

9 The prevalence of patent foramen ovale among patients with cryptogenic str

10 The association of patent foramen ovale and atrial septal aneurysm with str

11 Patients with a patent foramen ovale and ischemic stroke, transient isch

12 Patent foramen ovale and pulmonary arteriovenous shunts

13 ardiography identified three patients with a patent foramen ovale and right-to-left shunt flow while

14 occurred in 47% (including 17% with isolated patent foramen ovale), and 11% had undetermined stroke e

15 res, 15 patients had simultaneous closure of patent foramen ovale, and 19 patients had other various

16 inesis, persistent pulmonary hypertension, a patent foramen ovale, and free-floating right-heart thro

17 uding occult paroxysmal atrial fibrillation, patent foramen ovale, aortic arch atherosclerosis, atria

18 ion of cryptogenic embolism in patients with patent foramen ovale are administration of antithromboti

19 r device closure (9 secundum ASDs and 4 with patent foramen ovale associated with a cerebral vascular

20 valves has been reported in patients with a patent foramen ovale, carcinoid tumor of the lung, and a

21 Initial results using these tools to perform patent foramen ovale closure are described.

22 acement in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5.

23 th no apparent increased risk for concurrent patent foramen ovale closure or mitral or tricuspid repa

24 roup analysis demonstrated that simultaneous patent foramen ovale closure was not associated with an

25 nts with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offe

26 As a demonstration of both technologies, patent foramen ovale creation and closure was performed

27 reflect mainly the adult population, such as patent foramen ovale device closure and closure of posti

28 Closure of a patent foramen ovale for secondary prevention of cryptog

29 One possible exception is patent foramen ovale, for which high-risk features may w

30 Patent foramen ovale has been associated with increased

31 %), followed by ostium secundum ASD in 6 and patent foramen ovale in 4.

32 ificant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic

33 ment with warfarin or aspirin as part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS)

34 The Patent foramen ovale In Cryptogenic Stroke Study (PICSS)

35 geal echocardiograms in 11 patients showed a patent foramen ovale in one patient but no systemic sour

36 When pulmonary embolism coexists with a patent foramen ovale, increased pressure in the right at

37 Whether closure of a patent foramen ovale is effective in the prevention of r

38 the use of percutaneous closure devices for patent foramen ovale is reviewed.

39 presumed paradoxical emboli in patients with patent foramen ovale is unknown.

40 Transcatheter closure of patent foramen ovale may prevent a substantial proportio

41 secundum-type atrial septal defect (n=12) or patent foramen ovale (n=5) by a totally endoscopic appro

42 rocedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23

43 r closure of secundum atrial septal defects, patent foramen ovale, patent ductus arteriosus, stent pl

44 ned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic isc

45 A causal relationship between patent foramen ovale (PFO) and migraine has been hypothe

46 dary prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained isc

47 nsient ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cer

48 The role of a patent foramen ovale (PFO) as a risk factor for ischemic

49 Patent foramen ovale (PFO) can be detected in up to 43%

50 re well-documented, those for catheter-based patent foramen ovale (PFO) closure are still evolving.

51 date of patients who underwent transcatheter patent foramen ovale (PFO) closure for paradoxical embol

52 Percutaneous transcatheter patent foramen ovale (PFO) closure is now standard pract

53 Trials of patent foramen ovale (PFO) closure to prevent recurrent

54 The role of surgical closure of patent foramen ovale (PFO) for cerebral infarction (CI)

55 nts to close atrial septal defects (ASD) and patent foramen ovale (PFO) has a number of limitations,

56 Patent foramen ovale (PFO) has been associated with migr

57 to assess the risk of ischemic stroke from a patent foramen ovale (PFO) in the multiethnic prospectiv

58 The efficacy of closure of a patent foramen ovale (PFO) in the prevention of recurren

59 The patent foramen ovale (PFO) is a normal interatrial commu

60 Patent foramen ovale (PFO) is associated with cryptogeni

61 Patent foramen ovale (PFO) is associated with stroke, bu

62 Patent foramen ovale (PFO) is experiencing increased cli

63 Patent foramen ovale (PFO) is implicated in platypnea-or

64 Patent foramen ovale (PFO) is prevalent in patients with

65 Percutaneous transcatheter closure of patent foramen ovale (PFO) is used as an alternative to

66 A patent foramen ovale (PFO) may permit arterial embolizat

67 ive effectiveness of percutaneous closure of patent foramen ovale (PFO) plus medical therapy versus m

68 Patent foramen ovale (PFO) was detected with contrast in

69 o right-to-left shunted blood flow through a patent foramen ovale (PFO) would not be cooled.

70 atients with atrial septal aneurysm (SA) and patent foramen ovale (PFO), and to determine the efficac

71 sought to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA)

72 igraine headache symptoms in patients with a patent foramen ovale (PFO), both of which conditions are

73 udy was to evaluate the relationship between patent foramen ovale (PFO), ischemic stroke, and subclin

74 Controversy surrounds the issue of patent foramen ovale (PFO), stroke, and secondary preven

75 procedures to repair incidentally discovered patent foramen ovale (PFO).

76 se, resulting in a right-to-left shunt via a patent foramen ovale (PFO).

77 ed its utility in quantitative assessment of patent foramen ovales (PFO).

78 Patent foramen ovales (PFOs) are common congenital cardi

79 Whether closure of a patent foramen ovale reduces the risk of recurrence of i

80 l heart diseases causing stroke, the role of patent foramen ovale remains controversial.

81 theter closure of an atrial septal defect or patent foramen ovale to assess how the procedure affecte

82 Patent foramen ovales vary in both anatomical and functi

83 In the second group, the patent foramen ovale was not successfully created in 1 a

84 tudies of medical therapy (895 patients) for patent foramen ovale were included.

85 transcatheter closure or medical therapy for patent foramen ovale were required to include at least 1

86 All patent foramen ovales were completely closed in the firs

87 randomly assigned to undergo closure of the patent foramen ovale with the Amplatzer PFO Occluder or